#USA #New York #Class Action #Rosen Law Firm #Tandem Diabetes

Investigation of Tandem Diabetes Care, Inc. by Rosen Law Firm for Shareholder Claims

Rosen Law Firm Investigates Tandem Diabetes Care, Inc.

Rosen Law Firm, a globally recognized law firm advocating for investor rights, has announced its ongoing investigation into securities claims on behalf of the shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM). This follows serious concerns surrounding potential misleading business information that the company may have provided to its investors.

Background of the Investigation

The investigation was sparked by a press release issued by Tandem Diabetes on August 7, 2025, which disclosed a voluntary medical device correction affecting the tslim X2 insulin pumps. This announcement indicated a potential issue with the device that could lead to insulin delivery discontinuation, raising alarms among investors regarding the company’s transparency and operational integrity.

Following this notification, Tandem Diabetes saw a sharp decline in its stock value, witnessing a staggering 19.9% drop on the same day. The severity of this loss has prompted both concern and action among the investor community, leading many to question the legitimacy and reliability of the company's previous disclosures.

How Investors Can Benefit

Investors who purchased securities from Tandem Diabetes may have opportunities to seek compensation for their losses, especially if they believe they were misled. Rosen Law Firm emphasizes that prospective plaintiffs can engage in a class action lawsuit without incurring out-of-pocket fees through contingency fee arrangements.

For those interested in joining the class action, Rosen Law Firm provides various channels to gather more information. Investors can either visit the firm’s website or contact attorney Phillip Kim, who is available via a toll-free number for direct inquiries regarding the case.

Why Choose Rosen Law Firm?

Rosen Law Firm has a proven track record of successfully representing investors in securities class actions. The firm boasts a strong reputation, having achieved significant settlements, and has been recognized multiple times as a leader in this specialized field. In previous years, it has recovered hundreds of millions of dollars for investors, securing approximately $438 million alone in 2019. The founding partner, Laurence Rosen, has received multiple accolades, including recognition as a Titan of Plaintiffs' Bar by Law360 in 2020.

Given the complexities involved in securities class actions, the firm advises investors to select counsel carefully. Many firms may lack the necessary experience and resources to effectively handle class actions, making due diligence essential when choosing legal representation.

Follow for Updates

Investors interested in the developments of this case can follow Rosen Law Firm on social media platforms such as LinkedIn, Twitter, and Facebook for ongoing updates and information.

If you possess Tandem Diabetes securities and are interested in participating in this class action lawsuit or wish to learn more about the situation, do not hesitate to contact Rosen Law Firm or submit your inquiry through their official online form.